Charles N.S. Allen

Dr. Charles N.S. Allen

Temple University, Philadelphia, Pennsylvania, USA
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2022 in Viruses
Verified
Journal Article
Open access
PDF file
CACharles N.S. Allen
Charles N.S. Allen
SASterling P. Arjona
Sterling P. Arjona
MSMaryline Santerre
Maryline Santerre
BSBassel E Sawaya
Bassel E Sawaya
Metabolic reprogramming is a hallmark of cancer and has proven to be critical in viral infections. Metabolic reprogramming provides the cell with energy and biomass for large-scale biosynthesis. Based on studies of the cellular changes that contribute to metabolic reprogramming, seven main hallmarks can be identified: (1) increased glycolysis and lactic acid, (2) increased glutaminolysis, (3) increased pentose phosphate pathway, (4) mitochondrial changes, (5) increased lipid metabolism, (6) changes in amino acid metabolism, and (7) changes in other biosynthetic and bioenergetic pathways. Viruses depend on metabolic reprogramming to increase biomass to fuel viral genome replication and production of new virions. Viruses take advantage of the non-metabolic effects of metabolic reprogramming, creating an anti-apoptotic environment and evading the immune system. Other non-metabolic effects can negatively affect cellular function. Understanding the role metabolic reprogramming plays in viral pathogenesis may provide better therapeutic targets for antivirals.

1 September 2020 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
MSMaryline Santerre
Maryline Santerre
SASterling P. Arjona
Sterling P. Arjona
CACharles N.S. Allen
Charles N.S. Allen
NSNatalia Shcherbik
Natalia Shcherbik
BSBassel E Sawaya
Bassel E Sawaya

23 April 2021 in Autophagy
Verified
Journal Article
Closed access
MSMaryline Santerre
Maryline Santerre
SASterling P. Arjona
Sterling P. Arjona
CACharles N.S. Allen
Charles N.S. Allen
SCShannon Callen
Shannon Callen
SBShilpa Buch
Shilpa Buch
BSBassel E Sawaya
Bassel E Sawaya
Despite the promising therapeutic effects of combinatory antiretroviral therapy (cART), 20% to 30% of HIV/AIDS patients living with long term infection still exhibit related cognitive and motor disorders. Clinical studies in HIV-infected patients revealed evidence of basal ganglia dysfunction, tremors, fine motor movement deficits, gait, balance, and increased risk of falls. Among older HIV+ adults, the frequency of cases with SNCA/α-synuclein staining is higher than in older healthy persons and may predict an increased risk of developing a neurodegenerative disease. The accumulation of SNCA aggregates known as Lewy Bodies is widely described to be directly linked to motor dysfunction. These aggregates are naturally removed by Macroautophagy/autophagy, a cellular housekeeping mechanism, that can be disturbed by HIV-1. The molecular mechanisms involved in linking HIV-1 proteins and autophagy remain mostly unclear and necessitates further exploration. We showed that HIV-1 Vpr protein triggers the accumulation of SNCA in neurons after decreasing lysosomal acidification, deregulating lysosome positioning, and the expression levels of several proteins involved in lysosomal maturation. Viruses and retroviruses such as HIV-1 are known to manipulate autophagy in order to use it for their replication while blocking the degradative final step, which could destroy the virus itself. Our study highlights how the suppression of neuronal autophagy by HIV-1 Vpr is a mechanism leading to toxic protein aggregation and neurodegeneration. Abbreviations: BLOC1: Biogenesis of Lysosome-related Organelles Complex 1; CART: combinatory antiretroviral therapy; CVB: coxsackievirus; DAPI: 4’,6-diamidino-2-phenylindole; DENV: dengue virus; GFP: green fluorescent protein; HCV: hepatitis C virus; HCMV: human cytomegalovirus; HIV: human immunodeficiency virus; Env: HIV-1 envelope glycoproteins; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; VSV: Indiana vesiculovirus; LTR: Long Terminal Repeat; LAMP1: lysosomal associated membrane protein 1; MAP1LC3B/LC3B: microtubule associated protein 1 light chain 3 beta; MLBs: multilamellar bodies; RIPA: Radioimmunoprecipitation assay buffer; SDS-PAGE: sodium dodecyl sulfate-polyacrylamide gel electrophoresis; Tat: transactivator of TAR; TEM: transmission electron microscope; Vpr: Viral protein R

26 August 2019 in Aids Reviews
Verified
Journal Article
Closed access
BSBassel E Sawaya
Bassel E Sawaya
CACharles N.S. Allen
Charles N.S. Allen
MSMaryline Santerre
Maryline Santerre
SASterling P. Arjona
Sterling P. Arjona
YWYing Wang
Ying Wang
With the introduction of combinatory antiretroviral therapy, patients infected with human immunodeficiency virus type 1 (HIV-1) can live much longer than before. However, the identification of HIV-associated neurocognitive disorder (HAND), especially HIV-associated dementia in 15–20% of patients infected with HIV-1, indicates additional complexity. These disorders turn out to be subtype dependent. Recently, many studies are ongoing trying to understand how the virus induces neuronal injury which could lead to neurological dysfunction. Most of these studies are focusing on the HIV-1 release of proteins such as Tat. However, the exact role of these proteins and their involvement in neuronal degeneration remains unidentified; this is especially true since viral proteins from different HIV-1 subtypes differ in their ability to cause neuronal damage. This review describes the role of different HIV-1 subtypes, identifies probable pathways involved in neuronal damage, the contribution of different HIV-1 subtypes to the progression of HAND, and potential treatments for HAND.

23 November 2022 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
SASterling P. Arjona
Sterling P. Arjona
CACharles N.S. Allen
Charles N.S. Allen
MSMaryline Santerre
Maryline Santerre
SGScott Gross
Scott Gross
JSJonathan Soboloff
Jonathan Soboloff
BSBassel E Sawaya
Bassel E Sawaya
Introduction: Mitochondrial‐associated ER membranes (MAMs) control many cellular functions, including calcium and lipid exchange, intracellular trafficking, and mitochondrial biogenesis. The disruption of these functions contributes to neurocognitive disorders, such as spatial memory impairment and premature brain aging. Using neuronal cells, we demonstrated that HIV‐1 Tat protein deregulates the mitochondria.Methods& Results: To determine the mechanisms, we used a neuronal cell line and showed that Tat‐induced changes in expression and interactions of both MAM‐associated proteins and MAM tethering proteins. The addition of HIV‐1 Tat protein alters expression levels of PTPIP51 and VAPB proteins in the MAM fraction but not the whole cell. Phosphorylation of PTPIP51 protein regulates its subcellular localization and function. We demonstrated that the Tat protein promotes PTPIP51 phosphorylation on tyrosine residues and prevents its binding to VAPB. Treatment of the cells with a kinase inhibitor restores the PTPIP51‐VAPB interaction and overcomes the effect of Tat.Conclusion: These results suggest that Tat disrupts the MAM, through the induction of PTPIP51 phosphorylation, leading to ROS accumulation, mitochondrial stress, and altered movement. Hence, we concluded that interfering in the MAM‐associated cellular pathways contributes to spatial memory impairment and premature brain aging often observed in HIV‐1‐infected patients.

6 May 2022 in Viruses
Verified
Journal Article
Open access
PDF file
CACharles N.S. Allen
Charles N.S. Allen
MSMaryline Santerre
Maryline Santerre
SASterling P. Arjona
Sterling P. Arjona
LGLea J. Ghaleb
Lea J. Ghaleb
MHMuna Herzi
Muna Herzi
BSBassel E Sawaya
Bassel E Sawaya
Clinical studies indicate that patients infected with SARS-CoV-2 develop hyperinflammation, which correlates with increased mortality. The SARS-CoV-2/COVID-19-dependent inflammation is thought to occur via increased cytokine production and hyperactivity of RAGE in several cell types, a phenomenon observed for other disorders and diseases. Metabolic reprogramming has been shown to contribute to inflammation and is considered a hallmark of cancer, neurodegenerative diseases, and viral infections. Malfunctioning glycolysis, which normally aims to convert glucose into pyruvate, leads to the accumulation of advanced glycation end products (AGEs). Being aberrantly generated, AGEs then bind to their receptor, RAGE, and activate several pro-inflammatory genes, such as IL-1b and IL-6, thus, increasing hypoxia and inducing senescence. Using the lung epithelial cell (BEAS-2B) line, we demonstrated that SARS-CoV-2 proteins reprogram the cellular metabolism and increase pyruvate kinase muscle isoform 2 (PKM2). This deregulation promotes the accumulation of AGEs and senescence induction. We showed the ability of the PKM2 stabilizer, Tepp-46, to reverse the observed glycolysis changes/alterations and restore this essential metabolic process.